Cytokinetics
Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors to treat diseases characterized by impaired muscle function. With over 25 years of scientific expertise, the company aims to improve the lives of patients with debilitating muscle diseases through innovative medicines and a robust pipeline of therapies. Their mission is to be a leading muscle biology biopharmaceutical company that enhances patient health and extends independence.
Industries
Nr. of Employees
large (251-1000)
Patents
Products
Pipeline of investigational small-molecule sarcomere-targeted therapeutics
A portfolio of investigational small molecules designed to modulate sarcomere function for cardiovascular and neuromuscular indications; programs span discovery through late-stage clinical development.
Pipeline of investigational small-molecule sarcomere-targeted therapeutics
A portfolio of investigational small molecules designed to modulate sarcomere function for cardiovascular and neuromuscular indications; programs span discovery through late-stage clinical development.
Services
Two-year funded research fellowships providing independent research projects, mentorship, and training in muscle biology and drug discovery.
Seasonal internship placements offering project work, networking, and industry exposure for students and recent graduates.
Administration of limited managed access programs and open-label extension studies to provide investigational therapy access and collect long-term safety/efficacy data.
Two-year funded research fellowships providing independent research projects, mentorship, and training in muscle biology and drug discovery.
Seasonal internship placements offering project work, networking, and industry exposure for students and recent graduates.
Administration of limited managed access programs and open-label extension studies to provide investigational therapy access and collect long-term safety/efficacy data.
Expertise Areas
- Muscle biology and sarcomere pharmacology
- Preclinical translational pharmacology
- Medicinal chemistry and lead optimization
- ADME/DMPK and translational science
Key Technologies
- Small-molecule drug discovery
- In vivo disease models
- Next-generation sequencing (NGS)
- Proteomics
News & Updates
In 2020, Cytokinetics reported results of the GALACTIC-HF trial, published in NEJM, demonstrating the efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction.
FDA accepted New Drug Application for omecamtiv mecarbil for HFrEF
In 2022, the FDA accepted the NDA for omecamtiv mecarbil, a potential treatment for systolic heart failure.
Started Phase 3 SEQUOIA-HCM clinical trial of aficamten in oHCM
In 2022, Cytokinetics began the Phase 3 SEQUOIA-HCM trial for aficamten in obstructive hypertrophic cardiomyopathy.
Started Phase 2 cohort 4 of REDWOOD-HCM clinical trial of aficamten in nHCM
In 2022, the company initiated the fourth cohort of the Phase 2 REDWOOD-HCM trial for aficamten in non-obstructive hypertrophic cardiomyopathy.
A study published in the European Heart Journal in 2022 discussing the effects of omecamtiv mecarbil in heart failure patients.
A 2021 publication in Circulation: Heart Failure about a new troponin activator.
In 2020, Cytokinetics reported results of the GALACTIC-HF trial, published in NEJM, demonstrating the efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction.
FDA accepted New Drug Application for omecamtiv mecarbil for HFrEF
In 2022, the FDA accepted the NDA for omecamtiv mecarbil, a potential treatment for systolic heart failure.
Started Phase 3 SEQUOIA-HCM clinical trial of aficamten in oHCM
In 2022, Cytokinetics began the Phase 3 SEQUOIA-HCM trial for aficamten in obstructive hypertrophic cardiomyopathy.
Started Phase 2 cohort 4 of REDWOOD-HCM clinical trial of aficamten in nHCM
In 2022, the company initiated the fourth cohort of the Phase 2 REDWOOD-HCM trial for aficamten in non-obstructive hypertrophic cardiomyopathy.
A study published in the European Heart Journal in 2022 discussing the effects of omecamtiv mecarbil in heart failure patients.
A 2021 publication in Circulation: Heart Failure about a new troponin activator.